Tower Research Capital (TRC)’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.1K | Sell |
1,311
-22,392
| -94% | -$397K | ﹤0.01% | 3602 |
|
|
2026
Q1 | $449K | Buy |
+23,703
| New | +$383K | 0.01% | 983 |
|
|
2025
Q4 | – | Sell |
-11,909
| Closed | -$246K | – | 5550 |
|
|
2025
Q3 | $246K | Sell |
11,909
-4,135
| -26% | -$100K | 0.01% | 1321 |
|
|
2025
Q2 | $341K | Buy |
16,044
+6,769
| +73% | +$154K | 0.01% | 1310 |
|
|
2025
Q1 | $179K | Sell |
9,275
-7,661
| -45% | -$154K | 0.01% | 1429 |
|
|
2024
Q4 | $302K | Buy |
16,936
+15,440
| +1,032% | +$299K | 0.01% | 1403 |
|
|
2024
Q3 | $32.8K | Sell |
1,496
-67,324
| -98% | -$942K | ﹤0.01% | 2957 |
|
|
2024
Q2 | $537K | Buy |
68,820
+57,666
| +517% | +$311K | 0.01% | 1283 |
|
|
2024
Q1 | $46.2K | Sell |
11,154
-9,990
| -47% | -$39.7K | ﹤0.01% | 2334 |
|
|
2023
Q4 | $55.2K | Buy |
21,144
+14,384
| +213% | +$29.6K | ﹤0.01% | 3063 |
|
|
2023
Q3 | $12.6K | Buy |
6,760
+1,858
| +38% | +$3.54K | ﹤0.01% | 3880 |
|
|
2023
Q2 | $12.3K | Sell |
4,902
-15,972
| -77% | -$29.1K | ﹤0.01% | 3886 |
|
|
2023
Q1 | $36K | Sell |
20,874
-6,206
| -23% | -$16.9K | ﹤0.01% | 2816 |
|
|
2022
Q4 | $115K | Buy |
27,080
+15,689
| +138% | +$28.5K | ﹤0.01% | 1729 |
|
|
2022
Q3 | $14K | Buy |
11,391
+2,028
| +22% | +$2.29K | ﹤0.01% | 4226 |
|
|
2022
Q2 | $9K | Buy |
9,363
+5,187
| +124% | +$7.27K | ﹤0.01% | 4586 |
|
|
2022
Q1 | $10K | Buy |
4,176
+95
| +2% | +$239 | ﹤0.01% | 4344 |
|
|
2021
Q4 | $11K | Buy |
4,081
+1,722
| +73% | +$8.28K | ﹤0.01% | 4451 |
|
|
2021
Q3 | $12K | Sell |
2,359
-1,077
| -31% | -$7.73K | ﹤0.01% | 4170 |
|
|
2021
Q2 | $26K | Sell |
3,436
-1,381
| -29% | -$9.06K | ﹤0.01% | 3653 |
|
|
2021
Q1 | $28K | Buy |
4,817
+1,034
| +27% | +$6.67K | ﹤0.01% | 3619 |
|
|
2020
Q4 | $18K | Buy |
+3,783
| New | +$16K | ﹤0.01% | 3939 |
|
|
2018
Q2 | – | Sell |
-472
| Closed | -$6K | – | 4026 |
|
|
2018
Q1 | $6K | Buy |
+472
| New | +$5.9K | ﹤0.01% | 2668 |
|
|
2017
Q3 | – | Sell |
-300
| Closed | -$3K | – | 4113 |
|
|
2017
Q2 | $3K | Buy |
+300
| New | +$3.38K | ﹤0.01% | 2240 |
|
|
2016
Q4 | – | Sell |
-1,213
| Closed | -$11K | – | 4359 |
|
|
2016
Q3 | $11K | Sell |
1,213
-274
| -18% | -$1.98K | ﹤0.01% | 2013 |
|
|
2016
Q2 | $12K | Buy |
1,487
+274
| +23% | +$2.23K | ﹤0.01% | 2671 |
|
|
2016
Q1 | $8K | Buy |
1,213
+1,008
| +492% | +$8.15K | ﹤0.01% | 2237 |
|
|
2015
Q4 | $2K | Sell |
205
-1,023
| -83% | -$10.6K | ﹤0.01% | 3803 |
|
|
2015
Q3 | $13K | Buy |
+1,228
| New | +$14.7K | ﹤0.01% | 2105 |
|
|
2015
Q2 | – | Sell |
-5
| Closed | – | – | 4971 |
|
|
2015
Q1 | $0 | Buy |
+5
| New | +$57 | ﹤0.01% | 4876 |
|
Other funds holding SMMT
BBA
Tower Research Capital (TRC)'s SMMT Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Summit Therapeutics (SMMT) stake by 94% in Q2 2026, selling an estimated $397K and leaving 1,311 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3602.
Tower Research Capital (TRC) first reported a position in SMMT in Q1 2015 and has held it in 30 quarters since. The position peaked at $537K in Q2 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.
- Tower Research Capital (TRC) held 1,311 shares of Summit Therapeutics worth $19.1K as of Q2 2026.
- Tower Research Capital (TRC) sold 22,392 Summit Therapeutics shares in Q2 2026, an estimated $397K.
- Summit Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3602 holding.
- Tower Research Capital (TRC) first reported a position in Summit Therapeutics in Q1 2015 and has held it in 30 quarters since.
- Tower Research Capital (TRC)'s Summit Therapeutics position peaked at $537K in Q2 2024.
- 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.